Emerging Data Highlight Potential for Frontline Combinations in EGFR+ NSCLC

Ongoing research evaluating combination therapies for the frontline treatment of patients with EGFR-mutated non–small cell lung cancer could help improve survival outcomes for this patient population.

Related Keywords

South Korea ,Spain ,Madrid ,New York ,United States ,Mariposa ,Han ,Julia Rotow ,Dana Farber Cancer Institute ,European Society For Medical Oncology Congress ,Annual New York Lung Cancers ,Annual New York Lung Cancers Symposium ,European Society ,Medical Oncology Congress ,Egfr ,Nsclc ,Lung Cancer ,New York Lung Cancer Symposium ,